Seòmar agus comataidhean

The term “puberty-suppressing hormones” is non-specific, and could be applied to a range of medicines used for a variety of conditions.

In the context of the provision of gender identity healthcare to children and young people, I refer the member to question S6O-03286 on 28 March 2024. which is available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/official-report/search-what-was-said-in-parliament .

The Scottish Government does not routinely hold or collate this information. This information should be requested from the relevant Health Boards.

Scottish Government has confirmed funding for the Workforce Specialist Service (WSS) for 2024-25 and the current contract will be extended for a further 12 months. WSS provides confidential mental health assessment and treatment for regulated health, social care and social work professionals in Scotland.

The Digital Prescribing and Dispensing Pathways (DPDP) programme, is scheduled to replace the current paper prescription in Scotland with a digital approach by the end of this parliamentary term.

The business case which sets out the proposal for the next phase, and associated funding, for the programme are currently under consideration.

We do not know the numbers of children affected because the information has not been collected historically.

In response to the Independent Medicines and Medical Devices Safety Review (IMMDSR), the Scottish Government commissioned Public Health Scotland (PHS) to establish a medicines in pregnancy surveillance asset. This resource will support monitoring and reporting to progress improvements in the safe use of valproate and other teratogenic medicines in Scotland. Its first output is due to be published by PHS in April 2024 and will include prescribing data and trends for valproate and other anti-seizure medicines.

The Scottish Fire and Rescue Service (SFRS) naloxone programme was launched in February 2022, backed with investment of £89,000 from Scottish Government. The programme aims to establish a network of fire officers who will carry naloxone and be trained to administer it in the event of an emergency.

Since then, all SFRS staff have been invited to complete online training to learn more about drug deaths in Scotland and how naloxone can help someone in the event of an opioid overdose. To date, 3,379 out of all 7,619 staff have voluntarily completed the training.

There is additional training for Flexi Duty Officers (FDOs) who have volunteered to carry naloxone and there are now 31 trained FDO volunteers within SFRS who are able to do this. It is expected that over the next 6 weeks a further 130 FDO volunteers will be trained and equipped to carry and administer naloxone.

The carrying and administering Naloxone is considered by the Fire Brigades Union (FBU) to be a form of emergency medical response which currently sits out-with the role map of firefighters. SFRS has a desire to broaden the role of firefighters which would incorporate emergency medical response but this is dependent on reaching agreement with the FBU.

SFRS and Scottish Government are determined to fully implement this programme and will continue to work closely with all parties, including representative bodies, to overcome any barriers to its full implementation.

The Scottish Government will await the view and any decisions by the UK Government in relation to redress for anyone who was affected by exposure to valproate.

As set out in our letter to MSPs, this is because the recommendations on redress the UK Government is considering may involve a new agency and schemes that would be funded via a levy on manufacturers of medicines and medical devices and the Scottish Government has only limited powers under the devolution arrangements to impose levies.

We will of course update the Parliament about any important developments.

Data from the Scottish Health Survey did not inform the development of ‘Coronavirus (COVID-19): Scotland's Long Covid service’, published on 30 September 2021. This is because the results of the Scottish Health Survey 2021, which included questions on long COVID for the first time, were published on 8 November 2022.

Responsibility for service delivery rests locally with NHS Boards who configure services taking into account local circumstances and the reasonable needs of their patient populations.

As set out in my answer to question S6W-26000 on 18 March 2024, patient related experience and patient outcome measures will be recorded through NHS Boards’ use of the C-19 YRS digital screening tool. The provision of health data through this tool will assist in understanding the provision and effectiveness of long COVID services. Where possible, the data will be disaggregated by age, gender, ethnicity, and deprivation quintile. This will support understanding of any inequitable variation in service provision, experience and outcomes which may need to be addressed through service changes.

The long COVID National Strategic Network has contracted the University of Leeds to support the initial evaluation of long COVID services in Scotland, using data from the C19-YRS tool. The outputs of the evaluation are expected following the end of the financial year.

All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers .

NHS Inform has a dedicated long COVID microsite for people with ongoing symptoms after Covid-19, accessible at Long-term effects of COVID-19 | NHS inform . The information was updated in November 2023 following a user research exercise conducted with people living with long COVID to understand their experiences of accessing the information and identify areas for further development of the content.

More broadly, current COVID-19 specific guidance is still in place for the public and wider guidance for individuals and non-clinical workplaces, promoting a risk-based approach to building resilience to respiratory infections, including COVID-19. Any change in guidance will be driven by the data and evidence gathered, as well as expert advice.

We remain committed to delivering the £10 million long COVID Support Fund in full. The 2024-25 budget published on 19 December 2023 outlines our plans to make £3 million from the long COVID Support Fund available over 2024-25. We anticipate that the remainder of the funding will be allocated over 2025-26.

Following the publication of the COVID-19 Recovery Committee’s report on long COVID, we have confirmed that we will consider baselining long COVID Support funding for NHS Boards at a level to be determined based on progress made by NHS Boards over 2023-24.